B

중앙백신

072020KOSDAQ기초 의약물질 제조업

64.3 / 100

Reference Date: 2026-07-24

Financial Score24.0 / 40
News Sentiment21.3 / 25
Momentum7.0 / 20
Disclosure12.0 / 15
AI Analysis: PER is significantly undervalued vs. peers but Operating Profit is on a declining trend. Roughly flat over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Central Vaccine is a company specializing in the development and production of animal vaccines and biological products, focusing on disease prevention and control in the livestock industry. Recent outbreaks of African Swine Fever and Highly Pathogenic Avian Influenza have increased demand for vaccines, necessitating the development of new products to counteract the diminishing efficacy of existing ones. The company is expanding into new markets, including China and Brazil, to broaden its global presence.

Number of Employees

194people

Average Salary

57.1M KRW

Score Calculation Basis

Detailed Financial Score

PER
14.10Industry Average 25.446.5Point

Lower than industry avg (good)

PBR
0.81Industry Average 1.265.5Point

Lower than industry avg (good)

ROE
5.89Industry Average -6.033.5Point

Well below industry avg

Debt Ratio
5.08Industry Average 6.624.0Point

In line with industry avg

Trend 2023~20254.5 / 10 points
Revenue Growth Rate
2.0 / 3

Avg ▲8.3% (2-year basis)

Operating Profit Growth Rate
0.5 / 3

Avg ▼2.6% (2-year basis)

ROE Trend
2.0 / 4

Avg ROE 6.3% (declining, 3yr)

Detailed News Sentiment

3 totalPositive 3Neutral 0Negative 0Average Sentiment Score 85

Detailed Momentum

52-week position3.0Point

52w lower range (34%)

Current 9,250Won52-week high 10,14052-week low 8,780
1-month return3.0Point

1m 0.54% (flat)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

2 totalPositive 1Neutral 1Negative 0
  • Positive단일판매ㆍ공급계약체결2026-07-08
  • Neutral주식소각결정2026-06-25